Infliximab in inflammatory bowel disease

• Váldodahkkit: Konstantinos Papamichael (Dahkki), Steve Lin (Dahkki), Matthew Moore (Dahkki), Garyfallia Papaioannou (Dahkki), Lindsey Sattler (Dahkki), Adam S. Cheifetz (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: SAGE Publishing, 2019-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the inflammatory bowel diseases (IBD), Crohn's disease (CD), and ulcerative colitis. Twenty years ago, infliximab became the first anti-TNF agent approved for IBD. Data from randomized controlled trials, large...